TWI254639B - External preparations for enhancing cell activity - Google Patents
External preparations for enhancing cell activity Download PDFInfo
- Publication number
- TWI254639B TWI254639B TW092103549A TW92103549A TWI254639B TW I254639 B TWI254639 B TW I254639B TW 092103549 A TW092103549 A TW 092103549A TW 92103549 A TW92103549 A TW 92103549A TW I254639 B TWI254639 B TW I254639B
- Authority
- TW
- Taiwan
- Prior art keywords
- cell activity
- aqueous solution
- polysaccharide
- patent application
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Description
1254639 (1) 玖、發明說明 發明所屬之技術領域 本發明係關於一種促進細胞活性之外用劑,其具有改 善主要以花粉症或口內炎等各疾病之效果,且同時可應用 對細胞的電解質平衡、滲透壓平衡而將細胞活性化,進而 改善皮膚細胞的細胞功能降低所引起的各疾病。 先前技術 過去廣泛使用氯化鈉等無機鹽、葡萄糖等天然糖、或 血漿等作爲各種化粧品或醫藥外用劑之配合劑。例如,有 關含有氯化鈉等柔軟肌膚的乳霜者,已記載於 U.S.P.3 5 74 8 5 4號公報中,另一方面,含於礦物鹽類的皮 膚淸潔用品之申請案已於西德專利公開案第3 3 27 840號說 明書中被記載。且,有關混合葡萄糖對皮膚有潤滑作用的 糖成分之申請案已於U.S.P.3859436號公報中記載。又, 有關刮鬍子用的糊精水溶液之申請案已於U.S.P. 3 7 77 5 97 號公報中記載。 然而,這些過去的外用劑既使可達到皮膚殺菌及保護 皮膚的目的,但難以改善皮膚毛細管循環及功能降低所引 起的皮膚疾病、及色素沈澱、足癬、股癬、髮癬菌病、狐 臭、脫髮症、頭皮屑、癢等的皮膚細胞分裂功能降低所引 起的各種疾病。 因此,本發明者發現以活性化皮膚細胞,而改善因皮 膚細胞的細胞功能降低所引起的各疾病者,其爲於皮膚表 -6- (4) 1254639 〇. 1〜1 %的氯化鉀者爲解決課題的方法。 有關人類皮膚上病變的發炎 '色素沈澱、脫毛等各種 症狀,其原因與紫外線、化學物質等種種因素有關,其僅 限於細胞級的變化,具體而鹽爲細胞內小器官之一的粒線 體之膜或細胞膜障礙而言。即,粒線體的膜障礙引起細胞 內呼吸阻礙,進而降低細胞動力來源之 ATP (腺苷三磷 酸)的產生。因如此ATP的不足引起細胞膜能量運輸功 能的下降,而降低細胞與間質液間的物質輸送能力。結果 產生細胞內的葡萄糖等營養物質的不足,引起ATP酸性 降低之所引發的血液循環不佳。 產生如上述細胞級下的變化之原因有許多,特別爲對 口腔或鼻黏膜等細胞而言,經滲透壓作用而增加細胞間質 液,使疾病部位的細胞活性化。且,得知藉由木葡聚醣、 昆布多醣、與多醣體K的添加,可提高口腔或鼻黏膜等 細胞組織的免疫力或疫癒力。 實施方式 本發明基本配合爲將多醣體溶解於水溶液之促進細胞 活性之外用劑,對全體而言添加重量比爲,1〜5 〇 %的木 葡聚醣、1〜5 0 %的昆布多醣、與1〜5 〇 %的多醣體K (krestin )者。 木葡聚醣爲普遍存在於伸長•肥大的植物細胞之細胞 壁(一次壁)的組成糖鏈。植物種類的特異性係因木糖殘 基由半乳糖或岩藻糖-半乳糖鍵結所產生。該半乳糖殘基 -9- (7) 1254639 所謂水相成分(純水)係僅以純水製造之無油狀態, 完全無含製造化粧品等一般之外用劑時所使用的水溶性石 油系之界面活性劑等。因此,混合這些成分的水相成分 時,欲完全溶解各成分而於50〜100 °C下實施。 表1 疾病名 對象人數 有效性(點) 有效率(%) 男性型脫毛症 60 118 98 身心性脫毛症 50 60 60 痤瘡 3 0 5 8 97 紅臉 60 66 5 5 足癬 50 95 95 脂漏性皮膚炎 100 197 99 異位性皮膚炎 100 98 4 9 口內炎 50 100 100 花粉症 100 196 98 表1表示處方例1的藥理試驗所得結果。此時的有效 性,經使用本發明外用劑,無變化爲〇點,有痊癒變化爲 1點,確認有效果爲2點,而合計各個人之總點,並以下 述式算出有效性。且,本次試驗爲特別要確認花粉症之痊 癒效果,以1 0 0個患者作爲對象算出有效率。 【數1】 有效率= 總點 — 對象人 X 100 -12- (9) 1254639 其結果,得知木葡聚醣的濃度提高至處方例2以上 時,會有溶解後分離之現象,成爲不當的處方。又,木葡 聚醣之外,昆布多醣、多醣體K之任一必須於至少丨%以 上濃度時顯示有效性,又各濃度超過5 0 %時無法成爲處 方。 【發明的效果】1254639 (1) Field of the Invention The present invention relates to an agent for promoting cell activity, which has an effect of improving various diseases mainly such as hay fever or endophthalmitis, and at the same time, an electrolyte for cells can be applied. Balance and osmotic pressure balance activate cells, thereby improving various diseases caused by decreased cell function of skin cells. Prior Art In the past, inorganic salts such as sodium chloride, natural sugars such as glucose, and plasma have been widely used as a compounding agent for various cosmetic or pharmaceutical external preparations. For example, a cream containing soft skin such as sodium chloride is described in USP 3 5 74 8 5 4, and on the other hand, an application for a skin cleansing product containing mineral salts has been applied in West Germany. Patent Publication No. 3 3 27 840 is described in the specification. Further, an application for a sugar component in which a mixture of glucose and a skin is lubricated is described in U.S. Patent No. 3,859,436. Further, an application for an aqueous solution of a dextrin for shaving has been described in U.S. Patent No. 3, 7,775,978. However, these past external preparations can achieve the purpose of skin sterilization and skin protection, but it is difficult to improve skin diseases caused by skin capillary circulation and function reduction, and pigmentation, athlete's foot, femoral hernia, hair trout, and body odor. Various diseases caused by a decrease in skin cell division function such as alopecia, dandruff, and itching. Therefore, the present inventors have found that in order to activate skin cells and improve various diseases caused by a decrease in cell function of skin cells, it is a skin potassium chloride in the skin surface -6-(4) 1254639 〇. 1 to 1%. The method for solving the problem. The various symptoms of pigmentation, pigmentation, and hair loss on human skin are related to various factors such as ultraviolet rays and chemical substances, and are limited to cell-level changes. Specifically, salt is a mitochondria of one of the small organs in the cell. In terms of membrane or cell membrane barrier. That is, the membrane disorder of the mitochondria causes intracellular respiratory obstruction, which in turn reduces the production of ATP (adenosine triphosphate) which is a source of cellular power. Because of this, the lack of ATP causes a decrease in the energy transport function of the cell membrane, and reduces the ability of material transport between cells and interstitial fluid. As a result, insufficient nutrients such as glucose in the cells are generated, and blood circulation caused by a decrease in the acidity of ATP is caused. There are many reasons for the above-mentioned changes at the cell level, and particularly for cells such as the oral cavity or the nasal mucosa, the interstitial fluid is increased by osmotic pressure, and the cells at the disease site are activated. Further, it has been found that the addition of xyloglucan, laminarin, and polysaccharide K can improve the immunity or epidemic power of cell tissues such as the oral cavity or nasal mucosa. EMBODIMENT OF THE INVENTION The present invention is basically formulated as a preparation for promoting cell activity by dissolving a polysaccharide in an aqueous solution, and adding xyloglucan in a weight ratio of 1 to 5 % by weight to 1 to 50 % of laminarin, With 1 to 5 % of the polysaccharide K (krestin). Xyloglucan is a constituent sugar chain that is ubiquitous in the cell wall (primary wall) of elongated and hypertrophic plant cells. The specificity of the plant species is due to the xylose or fucose-galactose linkage of the xylose residue. The galactose residue-9-(7) 1254639 The so-called aqueous phase component (pure water) is an oil-free state produced only by pure water, and is completely free of water-soluble petroleum products used in the preparation of general external preparations such as cosmetics. Surfactant and the like. Therefore, when the aqueous phase components of these components are mixed, it is necessary to completely dissolve the components and carry out at 50 to 100 °C. Table 1 Number of patients with disease name Validity (dot) Effectiveness (%) Male type hair loss 60 118 98 Physical and mental hair loss 50 60 60 Acne 3 0 5 8 97 Red face 60 66 5 5 Foot 癣 50 95 95 Lipid leakage skin Yan 100 197 99 Atopic dermatitis 100 98 4 9 Endophthalmitis 50 100 100 Hay fever 100 196 98 Table 1 shows the results obtained by the pharmacological test of Formulation Example 1. In the case of the use of the external preparation of the present invention, no change is a defect, and the change is 1 point, and the effect is confirmed to be 2 points, and the total point of each person is added, and the validity is calculated by the following formula. In addition, in this test, it is necessary to confirm the healing effect of hay fever, and the efficiency is calculated for 100 patients. [Equation 1] Effectiveness = Total point - Target person X 100 -12- (9) 1254639 As a result, when the concentration of xyloglucan is increased to the prescription 2 or higher, there is a phenomenon of separation after dissolution, which is improper. Prescription. Further, in addition to xyloglucan, any of the laminarin polysaccharide and the polysaccharide K must exhibit a potency at a concentration of at least 丨% or more, and when the concentration exceeds 50%, it cannot be a place. [Effects of the Invention]
本發明係爲,對全體而言添加重量比爲,1〜5 0 %的 木葡聚醣、1〜5〇%的昆布多醣、與1〜5〇%的多醣體K (kre st in )的各成分水相成分中,可提高口腔或鼻黏膜等 細胞組織之免疫力或痊癒力,得到對花粉症等個人因素之 疾病亦有治療效果。The present invention is to add a weight ratio of 1 to 50% of xyloglucan, 1 to 5 % of laminarin, and 1 to 5 % of polysaccharide K (kre st in ). Among the components of the aqueous phase, the immunity or healing power of cell tissues such as the oral cavity or the nasal mucosa can be improved, and the disease can also be treated for diseases such as hay fever.
又,提高細胞組織的免疫力或痊癒力之同時,可製造 出與皮膚細胞間質液相同之環境,而預防粒線體的膜障礙 所引起的細胞內呼吸障礙、或細胞活動源之A T P (腺苷三 磷酸)生產降低,亦可保持電解質平衡、滲透壓平衡,並 促進皮膚細胞或黏膜細胞表層的障礙細胞之正常化,且對 男性脫毛症或痤瘡、足癖、脂漏性皮膚炎等難治療之疾病 極爲有用。本發明的意義極大對人類的貢獻亦大。 -14 -In addition, while improving the immunity or healing power of the cell tissue, the same environment as the interstitial fluid of the skin cells can be produced, and the intracellular respiratory disorder caused by the membrane disorder of the mitochondria or the ATP of the cell activity source can be prevented ( Reduced production of adenosine triphosphate), can maintain electrolyte balance, osmotic pressure balance, and promote the normalization of barrier cells in the surface of skin cells or mucosal cells, and difficult for male hair loss or hemorrhoids, athlete's foot, lipid leakage dermatitis, etc. The disease of treatment is extremely useful. The significance of the present invention greatly contributes to humans. -14 -
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002113217A JP3885204B2 (en) | 2002-04-16 | 2002-04-16 | External agent for promoting cell activity |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200407154A TW200407154A (en) | 2004-05-16 |
TWI254639B true TWI254639B (en) | 2006-05-11 |
Family
ID=29243346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092103549A TWI254639B (en) | 2002-04-16 | 2003-02-20 | External preparations for enhancing cell activity |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP3885204B2 (en) |
CN (1) | CN1240392C (en) |
AU (1) | AU2003213370A1 (en) |
HK (1) | HK1060048A1 (en) |
TW (1) | TWI254639B (en) |
WO (1) | WO2003086421A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005053841A (en) * | 2003-08-05 | 2005-03-03 | Kyouto Biomedical Science:Kk | Skin care preparation for external use |
CN1285382C (en) * | 2004-12-20 | 2006-11-22 | 凌沛学 | Transmission system of drug for nasal cavity of containing trehalose and byaluronic acid, and preparation method |
DE102007052380A1 (en) * | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolyte-containing preparations for use in dry mucous membranes |
JP5620168B2 (en) * | 2010-06-30 | 2014-11-05 | Dsp五協フード&ケミカル株式会社 | Xyloglucan-cation complex and stabilized composition containing the same |
CN103239571B (en) * | 2013-05-26 | 2014-09-03 | 广州市云桥生物科技有限公司 | Chinese medicine effective part composition for treating alopecia areata and preparation method thereof |
JP6313118B2 (en) * | 2014-05-16 | 2018-04-18 | 株式会社Cac | IgE inhibitor |
MX2018002533A (en) * | 2015-09-29 | 2018-06-27 | Kimberly Clark Co | Synergistic composition for maintenance of healthy balance of microflora. |
BR112019015239A2 (en) | 2017-02-28 | 2020-04-14 | Kimberly Clark Co | composition, and, method to maintain a healthy microflora balance in the urogenital area of a patient in need of it. |
FR3064473B1 (en) * | 2017-04-03 | 2021-02-12 | Basf Beauty Care Solutions France Sas | PROTECTIVE INGREDIENT OF THE BALANCE OF SKIN AND / OR MUCOSAL MICROBIAL FLORA |
BE1027425B1 (en) * | 2019-07-01 | 2021-02-08 | Aquilon Pharmaceuticals | INHALABLE COMPOSITION INCLUDING CYCLODEXTRIN FOR USE IN THE TREATMENT OF NASAL INFLAMMATIONS |
WO2023060613A1 (en) * | 2021-10-16 | 2023-04-20 | 南通市巨久新材料科技有限公司 | Peripheral blood mononuclear cell culture dish containing coriolus versicolor mushroom polysaccharide coating layer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03204804A (en) * | 1989-12-28 | 1991-09-06 | Mitsui Toatsu Chem Inc | Skin cosmetic |
JP2681527B2 (en) * | 1990-02-15 | 1997-11-26 | ジャパンファインケミカル株式会社 | Topical for promoting cell activity |
DE19710368A1 (en) * | 1997-03-13 | 1998-09-17 | Henkel Kgaa | Use of water-soluble beta-glucans as active ingredients for the production of therapeutic agents for skin treatment |
JP2002275046A (en) * | 2001-03-23 | 2002-09-25 | Kanebo Ltd | Agent for enhancing barrier against penetration through epidermis, and skin care composition |
-
2002
- 2002-04-16 JP JP2002113217A patent/JP3885204B2/en not_active Expired - Lifetime
-
2003
- 2003-02-20 TW TW092103549A patent/TWI254639B/en not_active IP Right Cessation
- 2003-03-05 AU AU2003213370A patent/AU2003213370A1/en not_active Abandoned
- 2003-03-05 WO PCT/JP2003/002536 patent/WO2003086421A1/en active Application Filing
- 2003-03-26 CN CNB031088236A patent/CN1240392C/en not_active Expired - Fee Related
-
2004
- 2004-04-23 HK HK04102877A patent/HK1060048A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2003086421A1 (en) | 2003-10-23 |
CN1451389A (en) | 2003-10-29 |
AU2003213370A1 (en) | 2003-10-27 |
CN1240392C (en) | 2006-02-08 |
JP3885204B2 (en) | 2007-02-21 |
HK1060048A1 (en) | 2004-07-30 |
TW200407154A (en) | 2004-05-16 |
JP2005289815A (en) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2681527B2 (en) | Topical for promoting cell activity | |
EP3125857B1 (en) | Compositions and methods for enhancing the topical application of a basic benefit agent | |
TWI254639B (en) | External preparations for enhancing cell activity | |
US20090191288A1 (en) | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | |
BR112016022159B1 (en) | POWDER AND METHOD TO IMPROVE THE TOPICAL APPLICATION OF AN ACID BENEFIT AGENT | |
US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
IT8024370A1 (en) | THERAPEUTIC COMPOSITION OF DIMETHYL SULPHOXIDE AND PROCEDURES FOR ITS USE | |
BR122014006936B1 (en) | PHARMACEUTICAL COMPOSITION UNDERSTANDING IN THE FORM OF AN INTRAVAGINAL RING | |
JP2008542324A (en) | Mucoadhesive xyloglucan-containing preparations useful in medical devices and pharmaceutical preparations | |
WO2008014685A1 (en) | Formulation containing trehalose for intraarticular injection | |
US20110082118A1 (en) | Onychomycosis Treatment Delivery System | |
HU211689A9 (en) | Treatment of disease employing hyaluronic acid and nsaids | |
CN108670889A (en) | A kind of toothpaste and preparation method thereof of anti-treating dental ulcer | |
CN104666112A (en) | Biological-activity hyaluronic acid toothpaste | |
TWI278318B (en) | External preparations for treating dermatitis | |
ES2240987T3 (en) | THERAPEUTIC COMPOSITION FOR EXTERNAL USE CONTAINING ADRENAL CORTICOESTEROIDS FOR THE TREATMENT OF DERMATITIS. | |
US8367683B2 (en) | Composition and method for treatment of warts | |
JPH0212443B2 (en) | ||
JP3503880B2 (en) | Oral composition | |
JP2723473B2 (en) | Uses of sulfated saccharides | |
RU2316333C1 (en) | Biologically active additive to agent for cosmetic healthy bath based on unossified antlers and magnesium and agent for cosmetic healthy bath based on the same | |
PT2288342T (en) | Magnesium system and use thereof in the cosmetics industry | |
CN108096133A (en) | Mobyneb Resina Draconis toothpaste | |
CN116583267A (en) | Targeted inactivated herpesvirus plaster pharmaceutical composition, and preparation method and application thereof | |
WO2006121209A1 (en) | Therapeutic agent for eczema and dermatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |